Arterial access-site complications after use of a vascular closure device related to puncture height

Benjamin Sartorius¹†, Michael Behnes¹†, Melike Ünsal¹, Ursula Hoffmann¹, Siegfried Lang¹, Kambis Mashayekhi², Martin Borggrefe¹ and Ibrahim Akin¹

Abstract

Background: To analyze differences of access-site complications related to the height of femoral arterial puncture and the use of a vascular closure device (VCD) following percutaneous coronary intervention (PCI).

Methods: A subgroup of the FERARI study being treated by femoral arterial access and valuable inguinal angiography before implantation of a VCD were included. Inguinal angiographies were systematically reviewed by two independent cardiologists to determine the correct height of femoral arterial puncture. Bleeding complications were documented within 30 days after PCI and were categorized according to BARC, TIMI, GUSTO and FERARI classifications.

Results: Femoral access point imaging was available in 95 patients compared to 105 patients without. The common femoral artery (CFA) was the most accessed artery in 41%, followed by the femoral arterial bifurcation (39%) and lower access sites distally from the femoral arterial bifurcation (low puncture: 20%). No differences were observed regarding indication of PCI, procedural data and anticoagulation therapies in relation to the heights of femoral arterial access (p > 0.05). Despite using VCD, arterial puncture at the CFA resulted in numerically highest numbers of overall bleedings (62%) compared to femoral arterial bifurcation (41%) (p = 0.059). 58% of bleedings occurred after arterial puncture below the femoral bifurcation (low puncture). Though no significant differences of bleedings regarding classifications of BARC, GUSTO, TIMI and FERARI as well as other vascular endpoints were observed regarding puncture height.

Conclusions: The present analysis demonstrates no significant differences of bleeding complications in relation to the height of femoral arterial puncture and subsequent use of a VCD.

Keywords: Bleeding, Vascular closure device, Femoral artery

Background

Bleedings are a common complication of percutaneous coronary interventions (PCI) both affecting the arterial access site and occurring in terms of general outcome. Bleedings do not only affect patients’ satisfaction, but do also increase mortality [1]. With specific regard to femoral arterial access-site bleedings, different strategies have been evaluated in order to reduce them. Besides manual compression and application of pressure bandages around the hips, so called vascular closure devices (VCD) were developed in the early 1990’s [2]. VCD were shown to reduce access-site bleedings and to reduce post intervention time to hemostasis [3, 4]. In contrast non-access site bleedings are supposed to result in a higher mortality risk compared to bleedings from primary access site [5]. Vavalle et al. showed in-hospital bleedings in acute coronary syndrome (ACS) patients to be associated with an increased risk of death, whereas mild access-site bleedings were not [6].

VCD have entered the medical practice in modern cardiac catheterization laboratories [3, 7]. Additionally this treatment has proven advantageous on the patients’ overall satisfaction and mobilization [8].

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Different characteristics were shown to predict arterial access-site complications after PCI, such as advanced age, female sex, bleeding predispositions or renal failure [9, 10]. However, there is no evidence currently available on how the height of femoral arterial puncture alters the occurrence of PCI-related bleedings.

Therefore, this sub-study of the FERARI trial [11, 12] aims to evaluate the differences of PCI-related bleedings depending on the height of femoral arterial puncture in combination with the treatment of a VCD.

**Methods**

**Study patients and data collection**

The present study is based on a subset of patients from the “Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions...
(FERARI)” study. The FERARI study is a single-center prospective, nonrandomized observational study being performed at the First Department of Medicine, University Medical Centre Mannheim (UMM) in Mannheim, Germany (clinicaltrials.gov identifier: NCT02455661). The study was approved by the medical ethics commission II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany. Written informed consent is obtained from all participating patients or their legal representatives [11]. Briefly, those patients with a valuable inguinal angiography before successful implantation of the AngioSealTM femoral VCD (Angio-Seal™; St. Jude Medical, Inc., St Paul, USA) following PCI were included. Patients with radial PCI and patients with a femoral PCI without any or a valuable inguinal angiography were excluded (Fig. 1). Performing femoral angiography belonged to the operators’ discretion and was performed to verify the location of puncture above or below the epigastric artery, to detect severe calcification of the puncture site or to alleviate difficult femoral or aortic passing.

Standardized angiography was performed from left anterior oblique (LAO) 30° and right anterior oblique (RAO) 30° view. A valuable inguinal angiography was defined, when the entire inguinal anatomy of the iliac and femoral arteries was documented, including the femoral bifurcation. All angiographies were systematically reviewed on the “OsiriX Imaging Software” (Pixmeo SARL, Switzerland) by two independent cardiologists in order to determine the correct height of femoral arterial puncture.

Femoral arterial puncture was performed by standardized Seldinger technique in all patients using a conventional stainless steel puncture needle (SFM Medical Devices®, Wächtersbach, Germany) (i.e. no micropuncture needle). Ultrasound guiding during arterial puncture or concomitant ipsilateral venous or arterial access was excluded. Number of needle passes was not documented, but was restricted to a maximum number of 5 in cases of difficult anatomy or calcification. The allowed French size in the FERARI study was 5–6 French. Only four different experienced interventional cardiologists performed PCIs in this study with a minimum volume of 300 PCI cases per year.

Table 1 Baseline characteristics of the study population

|                                  | All patients (n = 95) | Common femoral artery (n = 39) | Femoral bifurcation (n = 37) | Low puncture (n = 19) | p value |
|----------------------------------|----------------------|-------------------------------|-------------------------------|----------------------|---------|
| Age, mean ± SD                   | 69.3 ± 10.5          | 67 ± 10.6                     | 70.7 ± 9.7                   | 71.4 ± 11.4          | 0.142   |
| BMI, mean ± SD                   | 28.3 ± 5.6           | 26.4 ± 3.7                    | 29.5 ± 7.2                   | 29.6 ± 4.9           | 0.038   |
| Male, n (%)                      | 61 (64)              | 31 (80)                       | 23 (64)                      | 7 (37)               | 0.006   |
| Cardiovascular risk factors, n (%) |                      |                               |                              |                      |         |
| Arterial hypertension            | 71 (75)              | 26 (67)                       | 31 (86)                      | 14 (74)              | 0.228   |
| Diabetes                         | 34 (35)              | 9 (23)                        | 16 (44)                      | 9 (47)               | 0.089   |
| Smoking                          | 16 (17)              | 10 (26)                       | 3 (8)                        | 3 (16)               | 0.118   |
| Cardiac family history           | 12 (13)              | 3 (8)                         | 6 (16)                       | 3 (16)               | 0.484   |
| Prior medical history, n (%)     |                      |                               |                              |                      |         |
| Congestive heart failure         | 12 (13)              | 5 (13)                        | 5 (14)                       | 2 (11)               | 0.922   |
| Coronary artery disease         | 46 (48)              | 16 (41)                       | 20 (54)                      | 10 (53)              | 0.482   |
| Peripheral artery disease        | 6 (6)                | 3 (8)                         | 2 (5)                        | 1 (5)                | 1.000   |
| Chronic kidney disease           | 21 (22)              | 5 (13)                        | 10 (27)                      | 6 (32)               | 0.159   |
| Indication for PCI, n (%)        |                      |                               |                              |                      |         |
| STEMI                            | 6 (6)                | 2 (5)                         | 2 (5)                        | 2 (11)               | 0.741   |
| NSTEMI                           | 27 (28)              | 12 (31)                       | 11 (30)                      | 4 (21)               | 0.726   |
| Unstable AP                      | 19 (20)              | 9 (24)                        | 6 (16)                       | 4 (21)               | 0.748   |
| Stable AP                        | 19 (20)              | 6 (15)                        | 8 (21)                       | 5 (26)               | 0.592   |
| Other                            | 24 (25)              | 10 (26)                       | 10 (27)                      | 4 (21)               | 0.887   |
| Procedural data                  |                      |                               |                              |                      |         |
| Average Time                     | 47                   | 52                             | 51                             | 50                    |         |
| Drug eluting stents, n (%)       | 85 (90)              | 35 (90)                       | 33 (89)                      | 17 (90)              | 1.000   |
| Bare metal stents, n (%)         | 4 (4)                | 1 (3)                         | 2 (5)                         | 1 (5)                | 0.836   |
| Total stent length, mean ± SD    | 42.4 ± 29.7          | 39.5 ± 24.8                   | 42.3 ± 31.7                  | 48.3 ± 30.6          | 0.561   |
and an equal distribution of experiences with both the radial and femoral approach of each operator. Operators had already implanted at least 100 AngioSeal® femoral closure devices per year. All operators were equally experienced in both radial and femoral accessed interventions [11].

**Definition of height of femoral arterial puncture based on anatomical description**

The procedural X-ray contrast angiography of the femoral arteries was reviewed systematically and the access point was described anatomically. Arterial parts were classified into the external iliac artery (EIA), common femoral artery (CFA), femoral bifurcation, profund femoral artery (PFA) and superficial femoral artery (SFA). Based on these anatomic landmarks 4 different puncture heights were defined: high puncture at the EIA and above the inguinal ligament, femoral puncture at the CFA, femoral bifurcation and low puncture below the femoral bifurcation either at the PFA or SFA.

The border between EIA and CFA was drawn at the superficial epigastric artery as an indicator for the localization of the inguinal ligament. The femoral bifurcation was described as the area of 1 cm into each proximal and distal vessel branches. The PFA and SFA were distinguished by the typical lateral projection of the prominently visual course of the PFA and its side branches, namely the lateral circumflex femoral artery and the medial circumflex femoral artery.

**Post interventional procedure**

After successful PCI the VCD was implanted. Afterwards a circumferential pressure bandage is added to the puncture site to further support the prevention of bleedings. Patients were advised to remain in lying position (i.e. bed-rest) for 6 h. Pressure bandages were removed after a total of 12 h, unless access site bleedings occurred. Patients were not subject to early ambulation. All PCI patients remained hospitalized for at least 24 h, early ambulation was not allowed after PCI.

**Outcome definition and follow-up**

All patients were followed up during hospital stay and until 30-days after the index procedure directly and by standardized telephone visits. The primary outcome was defined as overall, access-site and non-access-site bleedings occurring within 30-days of follow-up. Overall bleedings were defined according to established bleeding classifications, i.e. “Bleeding Academic Research Consortium” (BARC) score, “The Thrombolysis in Myocardial infarction” (TIMI) score and

| Table 2 Anticoagulation of patients with recorded bleedings during PCI |
|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| **Pre-PCI, n (%)**               | All patients (n = 50)     | Common femoral artery (n = 24) | Femoral bifurcation (n = 15) | Low puncture (n = 11) | p value |
| ASS                              | 27 (54)                   | 11 (46)                   | 10 (67)                   | 6 (55)                    | 0.447          |
| Clopidogrel                      | 9 (18)                    | 5 (21)                    | 1 (7)                     | 3 (27)                    | 0.346          |
| Ticagrelor                       | 1 (2)                     | 0 (0)                     | 1 (7)                     | 0 (0)                     | 0.520          |
| Prasugrel                        | 5 (10)                    | 1 (4)                     | 3 (20)                    | 1 (9)                     | 0.284          |
| LMH                              | 2 (4)                     | 0 (0)                     | 1 (6)                     | 1 (9)                     | 0.265          |
| NOAC/OAC                         | 8 (16)                    | 4 (17)                    | 3 (20)                    | 1 (9)                     | 0.886          |
| None                             | 17 (34)                   | 11 (46)                   | 2 (13)                    | 4 (36)                    | 0.104          |
| INR, mean ± SD                   | 1.07 ± 0.23               | 1.09 ± 0.26               | 1 ± 0.08                  | 1.16 ± 0.33               | 0.066          |
| **Peri-PCI, n (%)**              |                           |                           |                           |                           |               |
| Heparin                          | 50 (100)                  | 24 (100)                  | 15 (100)                  | 11 (100)                  | 1              |
| GP IIIb/IIIA inhibitor           | 2 (4)                     | 1 (4)                     | 0 (0)                     | 1 (9)                     | 0.481          |
| Bivalirudin                      | 1 (2)                     | 0 (0)                     | 1 (7)                     | 0 (0)                     | 0.520          |
| **Post-PCI, n (%)**              |                           |                           |                           |                           |               |
| ASS + Clopidogrel                | 33 (66)                   | 14 (58)                   | 10 (67)                   | 9 (82)                    | 0.395          |
| ASS + Ticagrelor                 | 4 (8)                     | 1 (4)                     | 2 (13)                    | 1 (9)                     | 0.545          |
| ASS + Prasugrel                  | 6 (12)                    | 5 (21)                    | 1 (7)                     | 0 (0)                     | 0.279          |
| ASS + NOAC/OAC                   | 0 (0)                     | 0 (0)                     | 0 (0)                     | 0 (0)                     | -              |
| Thiopopyridine + NOAC/OAC        | 3 (6)                     | 1 (4)                     | 2 (13)                    | 0 (0)                     | 0.432          |
| Triple Therapy                   | 4 (8)                     | 3 (13)                    | 0 (0)                     | 1 (9)                     | 0.424          |

**LMH** low molecular heparin, **NOAC/OAC** Warfarin or one of the new oral anticoagulants (Rivaroxaban, Dabigatran, Apixaban); Tripl therapy: ASS + Clopidogrel + NOAC/OAC
the “Global Use of Strategies to Open Occluded Arteries” (GUSTO) score [6, 13, 14]. Access site bleedings were defined as hematomas, active bleedings, dissections, pseudoaneurysms, arteriovenous fistula, retroperitoneal hematoma and non-access-site bleeding. Access site bleedings were classified according to the study-specific FERARI classification, as described previously: [11] small (<5 cm), intermediate (5–15 cm), large (>15 cm) hematomas and complicated access-site bleedings.

Statistics
Statistical analyses were performed with SPSS Statistics (IBM, Armonk, NY) and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Data are presented as medians with interquartile ranges (25th and 75th percentiles) or as total numbers with group-related percentages. Normal distribution of data was tested with the Kolmogorov-Smirnov test. In case of normal distribution, the t-test was applied to compare scaled data. Scaled variables not normally distributed were compared using the Mann–Whitney U test. Categorical variables were compared using the chi-squared test, in case of low event rates the Fisher’s exact test was used. Risk factors for access site bleedings, which were shown to differ significantly between the two study groups, were adjusted using uni- and multivariate linear regression analyses for the predefined study outcomes representing the dependent variable. Level of significance was set at \( p < 0.05 \) (two-tailed), a statistical trend was defined at \( p < 0.1 \) (two-tailed).

Results
Study population
As illustrated in Fig. 1, of the initial study cohort of 400 patients, final number of 95 patients revealed valuable inguinal angiography as well as successful femoral PCI with a femoral VCD and were included for the present sub-analysis.

Figure 2, illustrates the distribution of the different arterial puncture sites. CFA was the most punctured arterial site (41%), followed by the femoral bifurcation (39%) and low puncture distally to the femoral bifurcation either at the PFA or SFA (20%). High punctures above the inguinal ligament were not performed within the present cohort.

Patient demographics were equally distributed between groups (Table 1), with a mean age of 67 to 71 years. Patients were often male, being mostly present in all subgroups (80% in common femoral, 64% in femoral bifurcation), despite in patients of the low puncture group (37%) \( (p = 0.006) \). Body mass index (BMI) was higher in femoral punctured patients compared to patients in the low puncture groups \( (p = 0.038) \). No further significant differences were found regarding cardiovascular risk factors between subgroups (Table 1). Accordingly the indications for PCI as well as mean procedural length or implanted stent lengths did not differ significantly (Table 1). The hospital stay time averaged at 9 days. During the 30 day follow-up period 11% of patients were rehospitalized, 4% received additional coronary angiography, while 3% received additional stent implantation. One stent thrombosis was documented, which resulted in the only death (1%).

Table 2 summarizes the different anticoagulant therapies being administered for all suspected bleedings. Neither pre-, peri- nor post-interventional combinations of anticoagulant therapies revealed any significant differences related to the different groups of arterial puncture height.

Bleedings related to the height of femoral arterial puncture
Overall bleedings occurred in more than half of all patients (53%) with prior femoral angiography, which was

Table 3 Bleeding rates depending on the presence of femoral angiography in PCI patients with a femoral VCD

|                     | Angiography \((n = 95)\) | No angiography \((n = 105)\) | \( p \) value |
|---------------------|--------------------------|-----------------------------|--------------|
| Overall bleedings, n (%) | 50 (53)                  | 61 (58)                     | 0.437        |
| Related to 5 F, ratio (%) | 6/14 (43)                | 7/15 (47)                   | 0.837        |
| Related to 6 F, ratio (%) | 44/81 (54)               | 54/90 (60)                  | 0.453        |
| BARC, n (%)          |                          |                             |              |
| 0                   | 45 (48)                  | 44 (42)                     | 0.437        |
| 1                   | 38 (40)                  | 50 (48)                     | 0.278        |
| 2                   | 10 (11)                  | 10 (10)                     | 0.813        |
| 3A                  | 0 (0)                    | 1 (1)                       | 1            |
| 3B                  | 2 (2)                    | 0 (0)                       | 0.224        |
| 3C                  | 0 (0)                    | 0 (0)                       | -            |
| 4                   | 0 (0)                    | 0 (0)                       | -            |
| 5                   | 0 (0)                    | 0 (0)                       | -            |
| TIMI, n (%)          |                          |                             |              |
| 0                   | 45 (47)                  | 44 (42)                     | 0.437        |
| 1                   | 50 (53)                  | 60 (57)                     | 0.522        |
| 2                   | 0 (0)                    | 1 (1)                       | 1            |
| 3                   | 0 (0)                    | 0 (0)                       | -            |
| GUSTO, n (%)         |                          |                             |              |
| 0                   | 45 (47)                  | 44 (42)                     | 0.437        |
| 1                   | 49 (52)                  | 60 (57)                     | 0            |
| 2                   | 0 (0)                    | 1 (1)                       | 1            |
| 3                   | 1 (1)                    | 0 (0)                       | 0.475        |
| FERARI, n (%)        |                          |                             |              |
| 0                   | 45 (47)                  | 44 (42)                     | 0.437        |
| 1                   | 25 (26)                  | 27 (26)                     | 0.923        |
| 2                   | 13 (14)                  | 10 (10)                     | 0.681        |
| 3                   | 9 (10)                   | 11 (10)                     | 0.813        |
| 4                   | 3 (3)                    | 3 (3)                       | 1            |
not significantly different compared to patients without femoral angiography (n = 105, overall bleeding rate 58%) \((p = 0.437)\) (Table 3). Most patients received 6 F introducer sheaths (femoral angiography: 85% versus 15%; no femoral angiography: 95% versus 5%). No differences of bleeding rates were found depending on the choice of sheath size or presence of angiography \((p > 0.05)\).

With regard to BARC, TIMI and GUSTO bleeding classifications 52.6% patients received a score of 1 or higher (Tables 3 and 4). Moderate bleedings (GUSTO 2) did not develop, whereas a severe bleeding (GUSTO 3) was only observed once (1.1%) in the common femoral subgroup. Including all primary access site bleedings, 61.5% femoral punctured patients showed bleedings (BARC, TIMI, GUSTO score \(\geq 1\)). In the femoral bifurcation group bleedings were spectated in 41% patients, low puncture showed 58% bleedings (Tables 3 and 4).

### Table 4: Bleedings according to heights of femoral arterial punctures

|                      | Common femoral artery \((n = 39)\) | Femoral bifurcation \((n = 37)\) | Low puncture \((n = 19)\) | \(p\) value |
|----------------------|-----------------------------------|---------------------------------|--------------------------|-----------|
| Overall bleedings, n \((\%\) | 24 (62)                           | 15 (41)                        | 11 (58)                  | 0.163     |
| Related to 5 F, ratio \((\%\) | 2/3 (67)                           | 2/8 (25)                       | 3/3 (100)               | 0.143     |
| Related to 6 F, ratio \((\%\) | 22/36 (61)                         | 13/29 (45)                     | 8/16 (50)               | 0.409     |
| BARC, n \((\%\) |                          |                                 |                         |           |
| 0                    | 15 (38)                           | 22 (60)                        | 8 (42)                  | 0.163     |
| 1                    | 16 (41)                           | 13 (35)                        | 9 (47)                  | 0.667     |
| 2                    | 7 (18)                            | 2 (5)                          | 1 (5)                   | 0.191     |
| 3A                   | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| 3B                   | 1 (3)                             | 0 (0)                          | 1 (5)                   | 0.677     |
| 3C                   | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| 4                    | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| 5                    | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| TIMI, n \((\%\) |                          |                                 |                         |           |
| 0                    | 15 (38)                           | 22 (59)                        | 8 (42)                  | 0.163     |
| 1                    | 24 (62)                           | 15 (41)                        | 11 (58)                 | 0.163     |
| 2                    | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| 3                    | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| GUSTO, n \((\%\) |                          |                                 |                         |           |
| 0                    | 15 (39)                           | 22 (60)                        | 8 (42)                  | 0.163     |
| 1                    | 23 (59)                           | 15 (41)                        | 11 (58)                 | 0.228     |
| 2                    | 0 (0)                             | 0 (0)                          | 0 (0)                   | -         |
| 3                    | 1 (3)                             | 0 (0)                          | 0 (0)                   | 1.000     |
| FERARI, n \((\%\) |                          |                                 |                         |           |
| 0                    | 15 (38)                           | 22 (60)                        | 8 (42)                  | 0.163     |
| 1                    | 12 (31)                           | 8 (22)                         | 5 (26)                  | 0.663     |
| 2                    | 6 (15)                            | 6 (16)                         | 1 (5)                   | 0.487     |
| 3                    | 5 (13)                            | 1 (3)                          | 3 (16)                  | 0.143     |
| 4                    | 1 (3)                             | 0 (0)                          | 2 (11)                  | 0.101     |

Mostly observed bleedings consisted of local hematomas (FERARI class 1–3) in 49.5% patients. Complicated access-site bleedings consisted of post-interventional open bleedings (2.1%), AV-dissection (2.1%), aneurysm spurious (1.1%).

### Discussion

The present subanalysis of the FERARI study evaluates differences of PCI-related bleedings depending on the height of femoral arterial puncture in combination with the treatment of a femoral VCD. It was demonstrated that the common femoral artery and femoral bifurcation were the most punctured access sites in the present cohort possibly revealing easiest anatomical accessibility. Arterial punctures below the femoral bifurcation was less performed. Accordingly, arterial puncture at the
bifurcation revealed a numerically lowest amount of bleedings (41%) compared to the CFA (62%) and lower punctures (58%), without reaching statistical cut-off.

In contrast, lower arterial punctures could not be shown to be associated with a worse outcome. It might me speculated whether a lower arterial puncture might be a valid alternative puncture site without increasingly risking bleedings.

No significant differences of baseline characteristics, indications of PCI and anticoagulation therapies were seen according to the described femoral arterial puncture sites, with the exception of a significantly higher number of female patients in the lower puncture group. This might indicate, that female patients are more likely to be punctured distally of the femoral bifurcation than male patients. Comparing female and male bleeding probabilities, no significance was recorded in the present study, although former studies have shown female gender having an increased bleeding risk [9]. Therefore the high number of bleedings in the lower puncture group might partially be a result of the high percentage of female patients (63%). The BMI differences might indicate that increased weight moves the operator to perform arterial puncture more distally. Additionally overweight and obese patients have lower bleeding rates [15].

The extend of documented bleedings was rarely of severe nature. Whether severe bleedings are associated similarly by different arterial puncture sites therefore needs to be investigated by large scale studies. The evaluation of anticoagulation therapies did not show any significant differences in each evaluated subgroup, making an uneven influence on the observed bleedings unlikely.

Study limitations
Patients were included retrospectively in the FERARI study after successful PCI and either VCD implantation or radial compression bracelet usage and therefore pre-selected and non-randomized. Only a single type of VCD was used in this study. Unsuccessful VCD implantations were not included into the FERARI study and could therefore not be analysed. Follow up period was limited to 30 days, which does not give any information on long term effects. Finally, bleeding events were only described clinically, without a standardized imaging technique such as duplex sonography.

Conclusions
In conclusion, the present study suggests, that bleeding risks associated with different punctured femoral arterial sites does not differ significantly. Therefore, neither CFA, femoral arterial bifurcation, nor profound and superficial femoral artery might have favoured the occurrence of bleeding. Weather the statistical trend being observed for a less bleeding rate at the femoral bifurcation is just statistical variance or due to a low study population needs to be investigated within a larger prospective studies.

Abbreviations
BARC: Bleeding Academic Research Consortium; CFA: Common femoral artery; FERARI: Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions; GUSTO: The Global Use of Strategies to Open Occluded Arteries; NOAC: New oral anticoagulants; PFA: Profound femoral artery; SFA: Superficial femoral artery; TIMI: Thrombolysis in Myocardial Infarction

Acknowledgement
None declared.

Funding
There are no funding sources to declare.

Availability of data and materials
The main data supporting the present findings is contained within the manuscript or referenced. The related dataset can be obtained directly from the author upon reasonable request.

Authors’ contributions
BS conceived this subgroup analysis, participated in its design and coordination, performed statistical analysis, carried out data analysis and interpretation and drafted the manuscript. MBe conceived the study well as this subgroup analysis, participated in data analysis and interpretation and helped draft the manuscript. MU participated in the study design and coordination, was responsible for initial data acquisition and analysis and helped to draft the manuscript. UH participated in the study design and coordination, as well as data acquisition and revised the manuscript. SL performed statistical analysis, participated in data analysis and interpretation, and helped to draft and revise the manuscript for important intellectual content. KM participated in the study design and coordination, as well as data acquisition and revised the manuscript. MBo participated in the study design and coordination, as well as data acquisition and revised the manuscript. IA conceived the study, participated in its design and coordination, participated in data analysis and interpretation and helped to draft and revise the manuscript for important intellectual content. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the medical ethics commission II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany. Written informed consent is obtained from all participating patients or their legal representatives [11].

Author details
1First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. 2Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.

Received: 10 August 2016 Accepted: 24 January 2017
Published online: 16 February 2017
References

1. Mehran R, Pocock S, Nolens E, Dangas GD, Clayton T, Clausen BE, Caieta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parisi H, Lansky AJ, Lincoff AM, Stone GW. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUTY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv. 2011;4(6):654–64.

2. Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: the second decade. J Am Coll Cardiol. 2007;50(17):1617–26.

3. Cox T, Blair L, Huntington C, Lincourtt A, Sing R, Heniford BT. Systematic review of randomized controlled trials comparing manual compression to vascular closure devices for diagnostic and therapeutic arterial procedures. Surg Technol Int. 2015;XXVII:32–44.

4. Holm NR, Sindberg B, Maeng M, Kaltoft A, Böttcher M, Krussell JK, Thuesen L, Terkelson C, Christiansen EH, Boxtler HE, Kristensen SO, Lassen JF, group C-U. Systematic comparison of manual compression and FemoSeal vascular closure device for closure after femoral artery access coronary angiography: the CLOSure dEvices Used in everyday Practice (CLOSE-UP) study. Euro Intervention. 2014;10(2):183–90.

5. Verheugt FW, Steinhibl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marsø SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and non-access site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(2):191–7.

6. Vavalle JP, Clare R, Chiswell K, Rao SV, Petersen JL, Kleiman NS, Mahaffey KW, Wang TY. Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv. 2013;6(7):709–17.

7. Schulz-Schupke S, Helde S, Gewalt S, Ibrahim T, Linhardt M, Haas K, Hoppe KL, Corliss MS, Hearne MJ, Kellett Jr MA, Watkins MW, Bradley WA, Hettleman BD, Kadish AH, Lincoff AM, Mehran R, Stone GW. Incidence, predictors and prognostic implications of bleeding complicating primary percutaneous coronary intervention: the ISAR-CLOSURE randomized clinical trial. JAMA. 2014;312(19):1981–90.

8. Duffin DC, Muhlstein JB, Allison SB, Home BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL, Lappe DL. Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invasive Cardiol. 2003;15(6):354–62.

9. Piper WD, Malenka DJ, Ryan JR Jr, Shubrooks Sr, verification PT, Tcheng J, O'Connor GT, Robb JF, Farell KL, Coslet MS, Heanne MJ, Kellett Jr MA, Watkins MW, Bradley WA, Hettleman BD, Silver TM, McGrath PO, O'Meara JR, Wernberg DE. Northern New England Cardiovascular Disease Study Group. Predicting vascular complications in percutaneous coronary interventions. Am Heart J. 2007;154(6):1022–9.

10. Matic DM, Assian MR, Stankovic S, Midovic IB, Marinikovic JM, Kocic NI, Antonijevic NM, Marjanovic MW, Nestic ZI, Prostran MS, Stankovic GN, et al. Incidence, predictors and prognostic implications of bleeding complicating primary percutaneous coronary intervention. Vojnosanit Pregl. 2015;72(7):589–95.

11. Behnes M, Unsal M, Hoffmann U, Fastner C, El-Battrawy I, Lang S, Mashayekhi K, Lehmann R, Borggreve M, Akin I. Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) study. Clin Med Insights Cardiol. 2015;9:97–103.

12. Fastner C, Behnes M, Unsal M, El-Battrawy I, Ansari U, Mashayekhi K, Hoffmann U, Lang S, Kuschyk J, Borggreve M, Akin I. Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. Heart Vessels. 2016. doi:10.1007/s00380-016-0901-3.

13. Mehran R, Rao SV, Shatt IL, Gibson CM, Caieta A, Eikelboom J, Kauf S, Wiviott SD, Meneghini R, Nolens E, Serebruany V, Valgimigli M, Visance P, Taggart D, Sabik JF, Curtin DE, Kruckow MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47.

14. Bovill EG, Tentin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Mills LD, Lambrew CT, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115(4):256–65.

15. Akin I, Tolg R, Hochadel M, Bergmann MW, Kehat BB, Schneider S, Senges J, Ruick KH, Richardt G, Nienaber CA, Group DDS. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv. 2012; 5(2):162–9.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit